Citius Oncology shares surge 20.49% premarket after announcing U.S. commercial launch of LYMPHIR™ cancer immunotherapy.

Citius Oncology (CTOR) surged 20.49% in premarket trading following the announcement of the U.S. commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL). The launch, supported by prior partnerships with McKesson and Cencora for distribution and Verix AI for commercial team optimization, marks a critical milestone in the company’s product commercialization strategy. Recent news of LYMPHIR’s U.S. availability, combined with international named patient program access in Southern Europe, signals expanding market reach and potential revenue growth. The sharp premarket rise directly aligns with this strategic advancement, reflecting investor optimism over the therapy’s commercial viability and Citius Oncology’s execution progress.